A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Authors :: Banerji U
Dean EJ
Pérez-Fidalgo JA
Batist G
Bedard PL
You B
Westin SN
Kabos P
Garrett MD
Tall M
Ambrose H
Barrett JC
Carr TH
Cheung SYA
Corcoran C
Cullberg M
Davies BR
de Bruin EC
Elvin P
Foxley A
Lawrence P
Lindemann JPO
Maudsley R
Pass M
Rowlands V
Rugman P
Schiavon G
Yates J
Schellens JHM
Source :: Clinical cancer research : an official journal of the American Association for Cancer Research, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Publication Year :: 2018
Publisher :: AMER ASSOC CANCER RESEARCH, 2018.

ISSN :: 15573265
Database :: OpenAIRE
Journal :: Clinical cancer research : an official journal of the American Association for Cancer Research, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Accession number :: edsair.RECOLECTA.....134ea8f3d21e133d616a6ae9ec55ff54

Tools